Patients Given Sunitinib Need Close Monitoring For Cardiac Problems

Sunitinib-a tyrosine-kinase inhibitor used to extend survival in patients with renal-cell carcinoma and gastrointestinal stromal tumours-has cardiotoxic effects. As such, patients given sunitinib, especially those with cardiac risk factors-need to be closely monitored. These are the conclusions of authors of an Article published in this week’s edition of The Lancet. [click link for full article]

More: continued here

Filed under: Cardiovascular on December 20th, 2007